AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Resmed DRC

31.940

-0.190-0.59%

Volume:1.67M

Turnover:53.71M

Market Cap:46.55B

PE:21.25

High:32.285

Open:32.050

Low:31.940

Close:32.130

52wk High:44.772

52wk Low:25.425

Shares:1.46B

Float Shares:145.49M

Volume Ratio:0.73

T/O Rate:1.15%

Dividend:0.35

Dividend Rate:1.09%

EPS(TTM):1.503

EPS(LYR):1.445

ROE:24.27%

ROA:14.00%

PB:5.07

PE(LYR):22.10

Loading ...

Overview Company News Filings

How Investors May Respond To ResMed (RMD) Dividend Hike And Ventilator Recall Headwinds

Simply Wall St.

ResMed (RMD) Faces A 10% Fair Value Gap As Dividend Rises 10%

Simply Wall St.

ResMed Bull Thinks Five-Year Outlook is Intact

Dividend Growth Stocks For Reliable Income When Oil Market Stress Rises

Simply Wall St.

Resmed Inc Stock (RMD) Moved Up by 3.01% on Aug 10: Key Drivers Unveiled

ResMed Likely to Start Raising Prices in December Quarter

ResMed Down Nearly 8%, on Pace for Largest Percent Decrease Since January 2025

ASX Biggest Losers

MT Newswires Live

Resmed Q4 Adjusted Earnings, Revenue Rise

MT Newswires Live

Resmed Bulls Think Acquisition Timing Looks Awkward

Resmed Cut to Neutral from Buy by Citigroup

3 US Healthcare Stocks Investors May Revisit As Inflation Pressures Build

Simply Wall St.

Resmed is Maintained at Hold by Jefferies

ResMed (RMD) After Russell Growth Index Exits Is The Undervalued Narrative Still Intact

Simply Wall St.

Resmed Willing to Cut Underperforming Assets

Resmed's $490M Sale Looks Strategically Sound

ResMed's $490 Million Sale of MatrixCare Not Material to Outlook, RBC Says

MT Newswires Live

Resmed is Maintained at Equal-weight by Wells Fargo

Resmed Bull Sees Divestment Sharpening Strategic Focus

Resmed's Matrixcare Sale May Hint at AI Disruption Risk

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/RMD.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RMD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","market":"AU","secType":"STK","nameCN":"Resmed DRC","latestPrice":31.94,"timestamp":1787292720000,"preClose":32.13,"halted":0,"volume":1672535,"delay":0,"changeRate":-0.005913476501711835,"nameEN":"Resmed DRC","floatShares":145494856,"shares":1457529700,"eps":1.503,"marketStatus":"Market Closed","change":-0.19,"latestTime":"08-21 16:12:00 AEST","open":32.05,"high":32.285,"low":31.94,"amount":53714261,"amplitude":0.010738,"askPrice":32.28,"askSize":40,"bidPrice":31.9,"bidSize":100,"shortable":3,"etf":0,"ttmEps":1.503,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":7,"adr":0,"adrRate":1,"exchange":"ASX","adjPreClose":32.13,"dividendRate":0.010861,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.7287655453530826,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RMD.AU","preClose":32.13,"auctionPrice":31.94,"auctionVolume":281552,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292600773}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","floatShares":145494856,"roa":"14.00%","roe":"24.27%","lyrEps":1.445,"volumeRatio":0.7287655453530826,"shares":1457529700,"dividePrice":0.3469,"high":32.285,"amplitude":0.010738,"preClose":32.13,"low":31.94,"week52Low":25.425,"pbRate":"5.07","psRate":"5.90","week52High":44.772,"institutionHeld":0,"latestPrice":31.94,"committee":0.428571,"eps":1.503,"divideRate":0.010861,"volume":1672535,"delay":0,"ttmEps":1.503,"open":32.05,"prevYearClose":35.646,"prevWeekClose":31.935,"prevMonthClose":29.702,"prevQuarterClose":28.795,"fiveDayClose":31.935,"twentyDayClose":27.349,"sixtyDayClose":28.874,"dividendPayoutRate":0.02326337710008864,"dividendGrowthYears":2,"dividendGrowthRate":0.076841184280566,"fiveYearAvgDividendRate":0.01298073865708731},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RMD.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-19","symbol":"RMD.AU","amount":0.066,"announcedDate":"2026-08-07","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-08-20","defaultRemindTime":1787097600000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-24","payableDate":"2026-08-20","currency":"USD","dateTimestamp":1787061600000,"payDate":"2026-09-24"},{"market":"AU","date":"2026-08-07","symbol":"RMD.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1786024800000,"reportTimeType":"","actualEps":null},{"date":"2026-05-13","symbol":"RMD.AU","amount":0.06,"announcedDate":"2026-05-01","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-05-14","defaultRemindTime":1778630400000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-05-14","currency":"USD","dateTimestamp":1778594400000,"payDate":"2026-06-18"},{"market":"AU","date":"2026-05-01","symbol":"RMD.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1777557600000,"reportTimeType":"pre","actualEps":null},{"date":"2026-02-11","symbol":"RMD.AU","amount":0.06,"announcedDate":"2026-01-30","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-02-12","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-19","payableDate":"2026-02-12","currency":"USD","dateTimestamp":1770728400000,"payDate":"2026-03-19"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RMD.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-08-19","recordDate":"2020-08-20","paymentDate":"2020-09-24","value":0.039,"currency":"USD"},{"executeDate":"2020-11-11","recordDate":"2020-11-12","paymentDate":"2020-12-17","value":0.039,"currency":"USD"},{"executeDate":"2021-02-10","recordDate":"2021-02-11","paymentDate":"2021-03-18","value":0.039,"currency":"USD"},{"executeDate":"2021-05-12","recordDate":"2021-05-13","paymentDate":"2021-06-17","value":0.039,"currency":"USD"},{"executeDate":"2021-08-18","recordDate":"2021-08-19","paymentDate":"2021-09-23","value":0.042,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RMD.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659150326","title":"How Investors May Respond To ResMed (RMD) Dividend Hike And Ventilator Recall Headwinds","url":"https://stock-news.laohu8.com/highlight/detail?id=2659150326","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659150326?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:26","pubTimestamp":1786627612,"startTime":"0","endTime":"0","summary":"In early August 2026, ResMed Inc. reported higher fourth-quarter and full-year sales and earnings, lifted its quarterly dividend to US$0.66 per share, and confirmed completion of a US$1.40 billion buyback program that has retired about 7.92% of its shares since 2014.\nAt the same time, management flagged a softer outlook tied to suspended ventilator sales after an FDA Class 1 recall, putting more emphasis on how resilient its broader sleep-health and digital platforms can be in supporting...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/how-investors-may-respond-to-resmed-rmd-dividend-hike-and-ve","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/how-investors-may-respond-to-resmed-rmd-dividend-hike-and-ve","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RMD","BK7501","ARTY","LU2177674079.SGD","FEBU","BK4585","BK4211","JOYT","RMD.AU","BK4504","DECU","VOTE","AIPO","LU2008162690.USD","RGLO","QTOC","BK4082","GXDW","BK7007","VTHR","LU0170899867.USD","AGIX","BK4548","LGHT","PMDE","CHAT","BK4588","ISBC","BK4567","IE00B5TLWC47.USD","VGFPF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658926851","title":"ResMed (RMD) Faces A 10% Fair Value Gap As Dividend Rises 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658926851","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658926851?lang=en_us&edition=fundamental","pubTime":"2026-08-12 11:49","pubTimestamp":1786506558,"startTime":"0","endTime":"0","summary":"ResMed (RMD) has given income focused investors fresh information to consider after it declared a quarterly dividend of $0.66 per share, a 10% increase, alongside its latest earnings and buyback update.\nSee our latest analysis for ResMed.\nResMed shares have recently picked up some momentum, with a 30 day share price return of 10.29% and a 90 day return of 11.10%. However, the year to date share price performance is down 8.16% and the 1 year total shareholder return has declined 19.86%, while...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/resmed-rmd-faces-a-10-fair-value-gap-as-dividend-rises-10","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/resmed-rmd-faces-a-10-fair-value-gap-as-dividend-rises-10","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B5TLWC47.USD","BK4567","BK4082","RMD","BK4504","RMD.AU","BK7501","LU0170899867.USD","BK4548","BK4585","LGHT","LU2008162690.USD","BK7007","LU2177674079.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658653349","title":"ResMed Bull Thinks Five-Year Outlook is Intact","url":"https://stock-news.laohu8.com/highlight/detail?id=2658653349","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658653349?lang=en_us&edition=fundamental","pubTime":"2026-08-11 09:29","pubTimestamp":1786411740,"startTime":"0","endTime":"0","summary":"0129 GMT - ResMed's bull at Macquarie thinks the breathing-tech provider's five-year outlook remains intact despite its June-quarter gross margin missing expectations. The dual-listed CPAP maker's 4Q 62.3% gross margin was 36 basis points short of the investment bank's expectations, and 46 basis points softer than consensus. However, Macquarie's analysts reminds clients that ResMed continues to expect a double-digit basis-point improvement to gross margin through 2030. Macquarie expects gross margin to widen to 62.9% by fiscal 2029, with EPS growth for the next three fiscal years of 9%, 6% and 10%, respectively. Macquarie raises its target price on ResMed's ASX-listed stock by 0.4% to 46.80 Australian dollars, and maintains an outperform rating. Shares are up 3.4% at A$31.11.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09766","TSLT","BK4504","TESL","BK4567","BK4082","TSLP","BK7007","TSLW","LGHT","TSII","RMD","TSLO","TSLL","07366","BK4585","LU2008162690.USD","TSYY","TSLG","CRSH","LU0170899867.USD","TSLR","TSL","07766","LU2177674079.SGD","TEST","TSLQ","TSLZ","BK4588","RMD.AU","TSLI","BK4548","TLA","ELOL","TSDD","TSLY","BK7501","IE00B5TLWC47.USD","09366","TSLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658575159","title":"Dividend Growth Stocks For Reliable Income When Oil Market Stress Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2658575159","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658575159?lang=en_us&edition=fundamental","pubTime":"2026-08-11 02:35","pubTimestamp":1786386955,"startTime":"0","endTime":"0","summary":"Oil markets are under pressure as the U.S. Strategic Petroleum Reserve sits below 300 million barrels and a historic supply disruption unsettles global trade routes. That kind of strain can ripple through inflation expectations, interest rates, and dividend plans. This article looks at three dividend growth stocks from our screener that are exposed to these headlines and explains why they may matter for investors who care about reliable and growing income streams.\nThe stocks covered below are...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/dividend-growth-stocks-for-reliable-income-when-oil-market-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/dividend-growth-stocks-for-reliable-income-when-oil-market-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2506951875.HKD","RMD.AU","LU1983299246.USD","VONE","ABFL","LU0690374615.EUR","LU0528227936.USD","DIVD","STXD","YLDE","RMD","FDVV","TACU","LU0950375773.USD","LU2404859667.USD","GB00B4QBRK32.GBP","CGDV","DIVL","LU2177674079.SGD","BK4585","LU2008162690.USD","LU2506951958.HKD","POT.NZ","BK4588","LU0823417737.USD","LU0289739699.SGD","LU2362540622.SGD","BK7007","BK7501","LU2506952097.USD","SYK","LU0823417653.USD","QDF","LU0690374961.EUR","VIG","QDEF","LU2089984988.USD","LU0114720955.EUR","LCOW","DURA","LU1791710582.SGD","LU2362541273.HKD","BGDV","QDPL","LU1791710400.SGD","IE00B5TLWC47.USD","IHI","BK4548","LGHT","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658930168","title":"Resmed Inc Stock (RMD) Moved Up by 3.01% on Aug 10: Key Drivers Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=2658930168","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658930168?lang=en_us&edition=fundamental","pubTime":"2026-08-10 23:15","pubTimestamp":1786374931,"startTime":"0","endTime":"0","summary":"• ResMed reported strong recurring revenue from its AirSense platform and software ecosystem.\n• Clinical insights suggest GLP-1 drugs increase sleep apnea diagnosis rates and patient engagement.\n• ResMed solidified market share as its primary competitor faces ongoing regulatory constraints.","market":"sh","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262093058-market-movers-rmd-20260810","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836757.USD","LU2362541513.USD","BSX.AU","BSX","ISUL","IE0002141913.USD","LU0070302665.USD","SG9999001176.USD","LU0011850046.USD","LU0048584097.USD","BK4567","LU1093756325.SGD","LU2087625088.SGD","LU1974910355.USD","RMD.AU","LU0267386448.USD","LU1989771016.USD","ISRG","LU0432979614.USD","LU0225283273.USD","LU0114720955.EUR","LU2491049909.HKD","LU2362540622.SGD","LU0353189763.USD","IE00BFXG0V08.USD","FXH","EKG","LGHT","LU0528227936.USD","BK4533","LU1791710400.SGD","LU2177674079.SGD","LU2491050071.SGD","IHI","LU0122379950.USD","LU1951198990.SGD","LU0238689110.USD","LU2008162690.USD","LU2063271972.USD","LU2265009873.SGD","IHF","BK7007","LU0823417653.USD","LU1093756168.USD","HUM.AU","LU2106854487.HKD","SG9999001176.SGD","RMD","HUM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658602261","title":"ResMed Likely to Start Raising Prices in December Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2658602261","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658602261?lang=en_us&edition=fundamental","pubTime":"2026-08-10 13:01","pubTimestamp":1786338060,"startTime":"0","endTime":"0","summary":"0501 GMT - ResMed is likely to counter September-quarter gross margin contraction by pushing through price increases over the remainder of its 2027 fiscal year, David L. Bailey of Morgan Stanley says. The analyst thinks that comments by the CPAP maker's management support his previously stated view that higher component costs will act as a headwind to margin expansion. He tells clients in a note that ResMed will likely raise prices after its fiscal first quarter, to meet its guidance for incremental gross margin expansion. MS keeps an equal-weight rating on ResMed's U.S.-listed stock and trims the target price by 0.9% to US$227.00. The stock last closed at US$211.94. ResMed's ASX-listed shares are up 4.0% at 30.02 Australian dollars.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2487616109.SGD","LU0006306889.USD","LU1720051108.HKD","LU1720051017.SGD","IE00B5TLWC47.USD","BK4585","LU2271345857.HKD","BK7501","LU0528227936.USD","LGHT","BK4516","BK4082","LU2357305700.SGD","LU0390134368.USD","LU2089283258.USD","LU2028103732.USD","RMD","LU0882574139.USD","LU0170899867.USD","LU0795875169.SGD","RMD.AU","LU1732800096.USD","BK4588","LU1244550221.USD","LU2008162690.USD","LU1989772840.SGD","LU0053666078.USD","LU1732799900.SGD","BK7007","LU1791710582.SGD","IE00B775SV38.USD","LU0225283273.USD","BK4567","LU0971096721.USD","LU2177674079.SGD","LU0098860793.USD","LU0267386448.USD","IAI","KBWB","IE00BZ1G4Q59.USD","LU2023251221.USD","BK4534","LU0158827948.USD","LU2111349929.HKD","LU2133065610.SGD","LU1162221912.USD","LU2089284900.SGD","LU1548497426.USD","LU0106261372.USD","LU1064131342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657915641","title":"ResMed Down Nearly 8%, on Pace for Largest Percent Decrease Since January 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2657915641","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657915641?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:58","pubTimestamp":1786111080,"startTime":"0","endTime":"0","summary":"ResMed Inc.  is currently at $205.73, down $17.51 or 7.84%--Would be lowest close since July 27, 2026, when it closed at $203.08--On pace for largest percent decrease since Jan. 31, 2025, when it fell 8.33%--Currently down two consecutive days; down 8.17% over this period--Worst two day stretch since the two days ending June 1, 2026, when it fell 8.35%--Down 2.49% this week; worst weekly performance since the week ending July 10, 2026, when it fell 2.75%--Down 2.49% month-to-date--Down 14.59% year-to-date--Down 30.81% from its all-time closing high of $297.36 on Sept. 8, 2021--Down 27.53% from 52 weeks ago , when it closed at $283.90--Down 29.96% from its 52-week closing high of $293.73 on Aug. 22, 2025--Up 12.53% from its 52-week closing low of $182.82 on June 2, 2026--Traded as low as $202.00; lowest intraday level since July 27, 2026, when it hit $195.80--Down 9.51% at today's intraday low; largest intraday percent decrease since June 24, 2024, when it fell as much as 12.83%--Second","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD","IE00B5TLWC47.USD","BK4588","BK7007","BK7501","BK4548","LU2177674079.SGD","RMD.AU","BK4082","BK4585","BK4567","BK4504","LU0170899867.USD","LU2008162690.USD","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657418693","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2657418693","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657418693?lang=en_us&edition=fundamental","pubTime":"2026-08-07 11:25","pubTimestamp":1786073116,"startTime":"0","endTime":"0","summary":"Here are the ASX-listed companies with the biggest losses on Friday.4DMedical : -8%, AU$4.25ResMed : -6%, AU$29.55EchoIQ : -6%, AU$1.46Phylogica : -5%, AU$2.02DroneShield : -5%, AU$2.16EQ Resources : -5%, AU$0.31Block: -4%, AU$113.35Zip : -4%, AU$2.84Brazilian Rare Earths : -4%, AU$4.30Macmahon Holdings : -3%, AU$1.00","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7094","RMD.AU","BRE.AU","BK7007","BK7016","ZIP.AU","4DX.AU","EQR.AU","BK7095","BK7093","MAH.AU","BK7158","PYC.AU","EIQ.AU","BK7501","DRO.AU","XYZ.AU","BK7067","BK7115"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657663326","title":"Resmed Q4 Adjusted Earnings, Revenue Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663326","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657663326?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:34","pubTimestamp":1786048476,"startTime":"0","endTime":"0","summary":"Resmed (RMD) reported Thursday Q4 adjusted earnings of $2.95 per diluted share, up from $2.55 a year earlier.Analysts polled by FactSet expected $2.89.Revenue for the quarter ended June 30 was $1.46 billion, up from $1.35 billion a year ago.Analysts surveyed by FactSet expected $1.46 billion.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B5TLWC47.USD","LU0170899867.USD","LGHT","BK4504","BK7501","BK4567","BK4082","BK4585","BK4588","LU2008162690.USD","LU2177674079.SGD","RMD","BK7007","RMD.AU","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653999244","title":"Resmed Bulls Think Acquisition Timing Looks Awkward","url":"https://stock-news.laohu8.com/highlight/detail?id=2653999244","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653999244?lang=en_us&edition=fundamental","pubTime":"2026-07-21 08:21","pubTimestamp":1784593260,"startTime":"0","endTime":"0","summary":"0021 GMT - ResMed's bulls at Canaccord Genuity think its latest acquisition has come at an awkward time for the breath-tech supplier. The broker's analysts say investors were just starting to get excited about ResMed's gross-margin expansion and potential to push earnings leverage, which may be challenged by the acquisition of the Noctrix startup. The analysts do see opportunity in trying to address restless leg syndrome, which is Noctrix's focus, but warn that ResMed shares are struggling for direction ahead of the company's 4Q update. Canaccord Genuity cuts its target price on ResMed's ASX-listed stock by 10% to 40.00 Australian dollars. Shares are down 0.5% at A$28.05.  Dow Jones NewswiresJuly 20, 2026 20:21 ET Copyright  2026 Dow Jones & Company, Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7007","IE00B5TLWC47.USD","LU2177674079.SGD","BK4548","LU2008162690.USD","LU0170899867.USD","BK4567","BK4588","RMD","RMD.AU","BK4585","BK4082","BK4504","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651876119","title":"Resmed Cut to Neutral from Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2651876119","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651876119?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:51","pubTimestamp":1783943460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RMD/analyst-ratings(END) Dow Jones NewswiresJuly 13, 2026 07:51 ET","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK4504","BK4548","RMD","BK4567","BK4588","BK4585","LU2008162690.USD","LGHT","BK7007","IE00B5TLWC47.USD","LU2177674079.SGD","LU0170899867.USD","RMD.AU","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651116911","title":"3 US Healthcare Stocks Investors May Revisit As Inflation Pressures Build","url":"https://stock-news.laohu8.com/highlight/detail?id=2651116911","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651116911?lang=en_us&edition=fundamental","pubTime":"2026-07-13 16:32","pubTimestamp":1783931562,"startTime":"0","endTime":"0","summary":"With crude and polypropylene costs rising after the Strait of Hormuz closure and fresh U.S. inflation data just ahead, many investors are rethinking how much risk they want to carry. Large cap defensive stocks can sometimes offer a middle ground by balancing exposure to inflation with the financial strength of bigger companies. This article looks at how the recent inflation shock and earnings season backdrop intersect with one U.S. Large-Cap Defensive Stocks screener and identifies 3 stocks...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/3-us-healthcare-stocks-investors-may-revisit-as-inflation-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/3-us-healthcare-stocks-investors-may-revisit-as-inflation-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DFUV","IUS","ARP","CLIX","DIVZ","RMD","CDC","ABT","BSR","CGDV","TEQI","FLV","EES","FXD","HIDV","ISBC","IMCG","HCSG","MDLV","PRVS","SAMT","SYK","ILCV","VTV","XOEX","BAMA","MODL","BKDV","ADPV","RMIF","VXZ","PSC","RHTX","SDOG","REGL","CGUS","BGSX","LGH","MAPP","FT","XLV","RMD.AU","LCG","EQRR","RULE","DECU","CGUI","VOTE","ABT.AU","FEBU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650134293","title":"Resmed is Maintained at Hold by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2650134293","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650134293?lang=en_us&edition=fundamental","pubTime":"2026-07-11 02:42","pubTimestamp":1783708920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RMD/analyst-ratings(END) Dow Jones NewswiresJuly 10, 2026 14:42 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4588","BK4082","BK4567","BK7501","IE00B5TLWC47.USD","RMD","BK4504","LU0170899867.USD","RMD.AU","BK4585","BK7007","LU2177674079.SGD","LGHT","LU2008162690.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650724629","title":"ResMed (RMD) After Russell Growth Index Exits Is The Undervalued Narrative Still Intact","url":"https://stock-news.laohu8.com/highlight/detail?id=2650724629","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650724629?lang=en_us&edition=fundamental","pubTime":"2026-07-10 04:46","pubTimestamp":1783629992,"startTime":"0","endTime":"0","summary":"Index changes put ResMed in focus\nResMed (RMD) has dropped from several Russell growth indices, including the Russell 1000 Growth and Russell 3000 Growth benchmarks. This change is putting fresh attention on how index adjustments could influence interest in the stock.\nSee our latest analysis for ResMed.\nResMed's index reclassification comes after a mixed price pattern, with the share price down 15.9% year to date. This comes despite a 6.6% 30 day share price return and a 1 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/resmed-rmd-after-russell-growth-index-exits-is-the-undervalu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/resmed-rmd-after-russell-growth-index-exits-is-the-undervalu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RMD.AU","BK4548","BK4588","AIPO","BK7007","VTHR","BK7501","BK4082","AGIX","RMD","BK4585","BK4567","LU2177674079.SGD","LGHT","IE00B5TLWC47.USD","LU0170899867.USD","BK4504","LU2008162690.USD","CHAT","QTOC","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650408912","title":"Resmed Willing to Cut Underperforming Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2650408912","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650408912?lang=en_us&edition=fundamental","pubTime":"2026-07-09 09:06","pubTimestamp":1783559160,"startTime":"0","endTime":"0","summary":"0106 GMT - ResMed's bulls at Jarden see the divestment of its MatrixCare business as a good example of the breath-tech supplier's willingness to recycle capital from business units that have not performed to expectations. With an unchanged overweight rating on ResMed's Australia-listed stock, the Jarden analysts write in a note that using proceeds from the US$490 million divestment to implement an accretive buyback shows good capital management. They trim their target price by 5.8% to 40.20 Australian dollars on earnings revisions and currency updates, but anticipate upside to EPS forecasts from a potential increase to the buyback. Shares are down 3.3% at A$30.17.  Dow Jones NewswiresJuly 08, 2026 21:06 ET Copyright  2026 Dow Jones & Company, Inc.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","RMD","IE00B5TLWC47.USD","BK7007","LGHT","LU2008162690.USD","LU0170899867.USD","BK4504","BK7501","BK4082","LU2177674079.SGD","RMD.AU","BK4567","BK4548","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650912678","title":"Resmed's $490M Sale Looks Strategically Sound","url":"https://stock-news.laohu8.com/highlight/detail?id=2650912678","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650912678?lang=en_us&edition=fundamental","pubTime":"2026-07-09 08:54","pubTimestamp":1783558440,"startTime":"0","endTime":"0","summary":"0054 GMT - ResMed's $490 million sale of its MatrixCare business looks strategically sound to its bull at Macquarie. One of the investment bank's analysts writes in a note that the divestment will allow the dual-listed breath-tech maker to sharpen its focus and to reallocate capital toward faster-growing core growth areas. Offloading a structurally challenged business and improving the company's growth profile makes sense to the analyst, who keeps an outperform rating on the stock. Stock catalysts include potential M&A activity and new product launches, the analyst adds. Macquarie lifts its target price on ResMed's ASX-listed stock by 0.2% to 46.60 Australian dollars. Shares are down 3.8% at A$29.995.  Dow Jones NewswiresJuly 08, 2026 20:54 ET Copyright  2026 Dow Jones & Company, Inc.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK4567","BK4548","IE00B5TLWC47.USD","BK4588","LU2008162690.USD","BK4082","BK4585","BK7007","LGHT","LU0170899867.USD","LU2177674079.SGD","RMD.AU","RMD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649733992","title":"ResMed's $490 Million Sale of MatrixCare Not Material to Outlook, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2649733992","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649733992?lang=en_us&edition=fundamental","pubTime":"2026-07-08 23:38","pubTimestamp":1783525109,"startTime":"0","endTime":"0","summary":"ResMed  is selling its MatrixCare business for a \"cheap\" price of $490 million, but the transaction is not material to the company's outlook, RBC Capital Markets said in a note Wednesday.The brokerage said that while it was unlikely that MatrixCare would be sold at the 25x EV/EBITDA multiple at which it was acquired in 2018, a low double-digit to mid-teens multiple might have been achievable, compared with the 8.4x multiple at which it was sold.The low multiple at which MatrixCare was sold raises questions about future artificial intelligence disruptions to ResMed's software business, according to the note.The transaction did not surprise, though, as MatrixCare was detracting from the overall growth of ResMed's residential care software segment, the brokerage said.RBC retained an outperform rating on the stock, but lowered its price target to $276 from $321.Shares of ResMed were down 4.9% in Wednesday trading.Price: 209.08, Change: -10.67, Percent Change: -4.86","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4504","BK7007","BK4567","IE00B5TLWC47.USD","BK4082","RMD.AU","BK4585","LU2177674079.SGD","BK4548","LU2008162690.USD","BK7501","LGHT","RMD","BK4588","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649960493","title":"Resmed is Maintained at Equal-weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2649960493","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649960493?lang=en_us&edition=fundamental","pubTime":"2026-07-08 18:50","pubTimestamp":1783507800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RMD/analyst-ratings(END) Dow Jones NewswiresJuly 08, 2026 06:50 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1035773651.USD","LU1267930573.SGD","LU1074936037.SGD","IE000M9KFDE8.USD","KBWB","RMD","LU0314106906.USD","LU0310800965.SGD","LU0742534661.SGD","BK7501","IE00B19Z3B42.SGD","LU1201861249.SGD","LU0070302665.USD","LU1280957306.USD","LU0208291251.USD","LU0251142724.SGD","LU0267386448.USD","BK7007","LU0162691827.USD","IYF","LU1668664300.SGD","LU0048573561.USD","LU0942090050.USD","PGF","RMD.AU","LU0154236417.USD","LU0310799852.SGD","LU0310800379.SGD","IE0002270589.USD","LU0072461881.USD","FTXO","LU1069347547.HKD","LU2361044865.SGD","BK4559","LU0868494708.USD","LU0170899867.USD","LU0211327993.USD","LU0417517546.SGD","LU1363072403.SGD","LU1894683348.USD","LGHT","BK4567","LU0980610538.SGD","LU1267930227.SGD","LU0128525689.USD","LU0648001328.SGD","LU1814569148.SGD","IE00B19Z3581.USD","LU2008162690.USD","IE00B7SZLL34.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649576449","title":"Resmed Bull Sees Divestment Sharpening Strategic Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2649576449","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649576449?lang=en_us&edition=fundamental","pubTime":"2026-07-08 12:35","pubTimestamp":1783485300,"startTime":"0","endTime":"0","summary":"0435 GMT - ResMed's bull at Morgans likes the divestment of its MatrixCare division for the way it sharpens the breath-tech provider's strategic focus. Analyst Derek Jellinek explains in a note that the US$490 million sale simplifies the investment case for dual-listed ResMed by exiting the somewhat peripheral vertical of aged care, and increasing its exposure to core franchises including sleep devices and masks. The divestment monetizes a mature asset and funds shareholder returns that should help support ResMed's share price, Jellinek tells clients. Morgans has a buy rating on ResMed's Australia-listed stock and a target price of 41.72 Australian dollars. Shares are down 0.3% at A$31.345.  Dow Jones NewswiresJuly 08, 2026 00:35 ET Copyright  2026 Dow Jones & Company, Inc.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5TLWC47.USD","LU0170899867.USD","LGHT","BK4504","BK7501","BK4567","BK4082","BK4585","BK4588","LU2008162690.USD","LU2177674079.SGD","RMD","BK7007","RMD.AU","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649952059","title":"Resmed's Matrixcare Sale May Hint at AI Disruption Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2649952059","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649952059?lang=en_us&edition=fundamental","pubTime":"2026-07-08 12:09","pubTimestamp":1783483740,"startTime":"0","endTime":"0","summary":"0409 GMT - ResMed's sale of its MatrixCare business at a lower-than-expected earnings multiple leads RBC analyst Craig Wong-Pan to suspect that the breath-tech maker may have been worried about AI disruption risks. Wong-Pan didn't expect a sale to match the 25X earnings ResMed paid in 2018, but had anticipated a multiple in the low double digits to mid teens. Instead, ResMed is selling at 8.9X earnings. He expects the majority of the US$490 million proceeds to be distributed to shareholders. \"We wonder if ResMed's decision to sell at this multiple partly reflects possible risks of future AI disruption to its software business.\" RBC has an outperform rating and US$321.00 target price on ResMed's U.S.-listed stock. Its ASX-listed shares are down 0.5% at 31.29 Australian dollars.  Dow Jones NewswiresJuly 08, 2026 00:09 ET Copyright  2026 Dow Jones & Company, Inc.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIX","CHAT","LU2008162690.USD","VTHR","BK7501","LGHT","AIPO","BK4082","IE00B5TLWC47.USD","RMD","BK7007","BK4548","LU0170899867.USD","ARTY","LU2177674079.SGD","BK4585","RMD.AU","QTOC","BK4504","BK4567","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":55,"code":"91000000","status":"200"}]}}